CD8A and neoplasm: Specifically, trilaciclib has been shown to enhance T-cell activation and the production of cytokines and chemokines [15, 20], to promote a favorable tumor immune microenvironment by increasing the intratumoral ratio of effector T cells to regulatory T cells (Tregs) and the number of activated T cells in the periphery [15], to inhibit immunosuppression by Tregs [15, 20], to significantly increase the expansion of T-cell clones [15, 17], and to enhance the induction of memory cluster of differentiation (CD)8+ T cells [21].